Retraction Note: Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-κB/TNF-α and TGF-β/Smad pathways.
Guo NF, Cao YJ, Chen X, Zhang Y, Fan YP, Liu J, Chen XL.
Guo NF, et al. Among authors: zhang y.
Eur Rev Med Pharmacol Sci. 2023 Jul;27(14):6472. doi: 10.26355/eurrev_202307_33113.
Eur Rev Med Pharmacol Sci. 2023.
PMID: 37522656
Free article.
The article "Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-kappaB/TNF-alpha and TGF-beta/Smad pathways", by N.-F. Guo, Y.-J. Cao, X. Chen, Y. Zhang, Y.-P. Fan, J. Liu, X.-L. Chen published in Eur Rev Med Pharmacol Sci 2019; …
The article "Lixisenatide protects doxorubicin-induced renal fibrosis by activating wNF-kappaB/TNF-alpha and TGF-beta/Smad pathways", by N.- …